Amneal Pharmaceuticals Wins FDA Approval for Generic Albuterol Inhaler
Amneal Pharmaceuticals Inc. has received FDA approval for its generic albuterol sulfate inhalation aerosol, marking its second complex respiratory product approval in Q4 2025. This strengthens Amneal's position in the respiratory drug market.
Amneal Pharmaceuticals Inc. has received U.S. Food and Drug Administration (FDA) approval for its albuterol sulfate inhalation aerosol (90 mcg per actuation), the generic equivalent of PROAIR® HFA. This marks Amneal’s second complex respiratory therapeutic product approval in the fourth quarter of 2025, following the recent FDA approval of its beclomethasone dipropionate inhalation aerosol, a generic equivalent of QVAR®. These approvals strengthen Amneal’s presence in the respiratory drug delivery market. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amneal Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9594778-en) on December 02, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
